Cerus Corp stock (US1570851014): turnaround hopes after sharp rally in blood safety specialist
Cerus Corp (CERS) stock has seen a significant rebound, attracting renewed investor interest after a challenging 2024. The blood safety company, known for its INTERCEPT Blood System, is gaining attention as a turnaround story among healthcare penny stocks. Despite historically reporting net losses, the company aims for improved profitability through sales growth and cost control, particularly as it pursues expansion into red blood cell applications.
Cerus Corp stock (US1570851014): blood safety specialist in focus after Q1 2026 update
Cerus Corp recently reported its Q1 2026 results, highlighting revenue growth driven by increased adoption of its INTERCEPT blood safety systems, particularly for platelets in the US and Europe. The company, which specializes in pathogen reduction technologies, is aiming for profitability by focusing on recurring revenue from disposable kits and exploring collaborations with public agencies. While its core business is strong, Cerus navigates a highly regulated medical technology market with ongoing innovation and clinical data to support broader adoption.
Cerus Corp stock (US1570851014): blood safety specialist back in focus after latest business update
Cerus Corp (CERS) is back in focus following business updates on its INTERCEPT blood safety platform, crucial for safer transfusions in hospitals. The company's model relies on recurring revenue from single-use kits for platelets and plasma, with long-term potential in red blood cells. US investors gain exposure to a specialized healthcare sector tied to public health and demographics, appealing to those comfortable with mid-cap healthcare growth and long-term trends.
Cerus Corp stock (US1570851014): Recent 2.21% gain amid mixed signals
Cerus Corp (CERS) shares saw a 2.21% increase to $1.39 on Nasdaq on July 25, 2025, supported by moving averages despite an overall negative "sell candidate" score. The company focuses on its INTERCEPT Blood System for blood safety, developing and marketing technology to inactivate pathogens in blood products. Investors are watching for trading volume trends and resistance levels, while highlighting the company's role in the growing medical device sector.
Cerus Is Finding Its Next Gear In Blood Safety
Cerus Corporation is experiencing an inflection point with accelerating commercial traction, particularly strong platelet franchise sales and rapidly growing U.S. INTERCEPT Fibrinogen Complex (IFC) volumes, leading to raised 2026 product revenue guidance. While the company faces risks associated with regulatory hurdles for its red blood cell program and current negative profitability, its narrow technical moat and potential for re-rating based on improved execution and positive catalysts offer upside for risk-tolerant investors. The transition of leadership and upcoming clinical readouts are key milestones to watch.
Cerus corp COO Vivek Jayaraman sells $50,001 in common stock By Investing.com
Vivek K. Jayaraman, COO of Cerus Corp (NASDAQ:CERS), sold 16,667 shares of common stock for $50,001 on May 1, 2026, through a pre-arranged trading plan. Despite the stock surging 99% over the past year, analysts do not expect the company to be profitable this year. Cerus Corporation recently exceeded Q1 2026 earnings and revenue expectations, reporting EPS of -$0.01 and revenue of $59.9 million.
Cerus corp COO Vivek Jayaraman sells $50,001 in common stock By Investing.com
Vivek K. Jayaraman, COO of Cerus Corp (NASDAQ:CERS), sold 16,667 shares of common stock for $50,001 on May 1, 2026, as part of a pre-arranged trading plan. Following this transaction, Mr. Jayaraman directly owns 1,673,374 shares. Despite the sale, the stock has surged 99% over the past year, while analysts do not anticipate profitability this year.
Cerus corp COO Vivek Jayaraman sells $50,001 in common stock
Cerus Corp's COO, Vivek K. Jayaraman, sold 16,667 shares of common stock for $50,001 on May 1, 2026, pursuant to a pre-arranged trading plan. The company's stock has seen a 99% surge over the past year. Despite recent positive quarterly earnings exceeding expectations with an EPS of -$0.01 and revenue of $59.9 million, analysts do not anticipate profitability this year.
Cerus corp COO Vivek Jayaraman sells $50,001 in common stock By Investing.com
Cerus corp COO Vivek Jayaraman sold 16,667 shares of common stock for $50,001 on May 1, 2026, pursuant to a pre-arranged 10b5-1 trading plan. Despite the sale, he still directly owns 1,673,374 shares. This transaction follows Cerus Corporation exceeding expectations in its first-quarter 2026 earnings, though analysts do not anticipate profitability for the company this year.
Cerus (CERS) COO sells 16,667 shares in planned 10b5-1 trade
Cerus COO Vivek K. Jayaraman sold 16,667 shares of the company's common stock at $3.00 per share on May 1, 2026. This transaction was executed as a pre-planned divestment under a Rule 10b5-1 trading plan. Following the sale, Jayaraman directly holds 1,673,374 shares of Cerus common stock.
Cerus corp COO Vivek Jayaraman sells $50,001 in common stock
Cerus corp COO Vivek Jayaraman sold 16,667 shares of common stock for $50,001 on May 1, 2026, pursuant to a pre-arranged trading plan. The stock has seen a 99% surge over the past year, trading near its 52-week high. Analysts do not expect the company to be profitable this year, despite exceeding Q1 2026 earnings and revenue forecasts.
Cerus (NASDAQ:CERS) Upgraded by Zacks Research to Hold Rating
Zacks Research upgraded Cerus (NASDAQ:CERS) from a "strong sell" to a "hold" rating, contributing to a consensus "Hold" rating from analysts with an average target price of $4.00. The company recently reported better-than-expected Q1 results, with revenue up 22.6% year-over-year and a narrower EPS loss, alongside positive operating cash flow. Despite positive earnings, the company's full-year 2026 revenue guidance falls below consensus estimates, and there has been significant insider selling which may affect investor sentiment.
Cerus (NASDAQ:CERS) Upgraded by Wall Street Zen to Buy Rating
Wall Street Zen upgraded Cerus (NASDAQ:CERS) from a "hold" to a "buy" rating, influenced by better-than-expected Q1 results and positive operating cash flow. Despite recent insider selling and a Q1 revenue beat, the company's full-year 2026 revenue guidance was slightly below consensus, leading to a mixed analyst outlook with two "Buy" and two "Sell" ratings and a consensus "Hold." The report highlights insider selling and mixed institutional flows as potential concerns for investor sentiment.
Insider sale filings: CERS (NASDAQ: CERS) reports restricted stock dispositions
CERUS CORP (CERS) has reported insider sales of restricted common stock through a Form 144 filing. The filing indicates the proposed and recent dispositions of shares by an affiliate, Vivek K Jayaraman, including sales of 165,200 shares on March 13, 2026, and 34,094 shares on March 6, 2026, with associated transaction values. The document also details the grant dates and share counts of the restricted stock.
[144] CERUS CORP SEC Filing
This SEC filing (Form 144) details sales of restricted common stock by Richard J. Benjamin of CERUS CORP (CERS) in March 2026. The filing indicates several transactions, including a significant sale of 101,740 shares on March 13, 2026, totaling over $168,000. It also provides key terms related to restricted stock and Form 144 requirements, noting the neutral impact of such routine disclosures.
Cerus (NASDAQ:CERS) Reaches New 12-Month High After Better-Than-Expected Earnings
Cerus (NASDAQ:CERS) shares hit a new 52-week high after the company reported stronger-than-expected Q1 earnings, beating revenue and EPS estimates. Despite the positive earnings, the company's full-year 2026 revenue guidance fell below consensus, and insiders have recently sold a significant number of shares. Analyst sentiment is mixed, with BTIG upgrading the stock to a "Buy" with a $4 price target, while others maintain a "Hold" or "Sell" rating.
Cerus Corporation (NASDAQ:CERS) Q1 2026 Earnings Call Transcript
Cerus Corporation reported strong Q1 2026 results, with product revenue up 24% to $53.7 million, leading to an increased full-year product revenue guidance of $227 million to $231 million. The company is experiencing significant growth in its global platelet franchise and accelerating demand for its Intercept Fibrinogen Complex (IFC) business in the U.S., driven by new agreements and market penetration. Cerus also highlighted progress in red blood cell (RBC) program development and the upcoming U.S. FDA submission for its INT 200 illuminator.
[8-K] CERUS CORP Reports Material Event
Cerus Corporation reported strong financial results for the first quarter of 2026, with total revenue increasing by 23% to $59.9 million and product revenue by 24% to $53.7 million. The company significantly narrowed its net loss to $1.6 million and saw increased demand for its INTERCEPT Fibrinogen Complex. Based on this performance, Cerus raised its full-year 2026 product revenue guidance to a range of $227 million to $231 million.
Earnings call transcript: Cerus Corporation Q1 2026 beats EPS forecast
Cerus Corporation reported strong Q1 2026 results, with EPS of -$0.01 significantly exceeding the -$0.05 forecast and revenue reaching $59.9 million against an anticipated $56.17 million. This performance led to a 5.73% increase in stock price after hours. The company reaffirmed its full-year product revenue guidance, driven by growth in North American and EMEA markets, particularly its INTERCEPT platform and IFC business, while managing expenses despite inflationary pressures and foreign currency impacts.
Cerus: Q1 Earnings Snapshot
Cerus Corp. (CERS) reported a first-quarter loss of $1.6 million, or 1 cent per share. The biomedical products company also announced revenues of $53.7 million for the period and anticipates full-year revenue to be between $227 million and $231 million.
Cerus: Q1 Earnings Snapshot
Cerus Corp. (CERS) reported a first-quarter loss of $1.6 million, equating to 1 cent per share. The biomedical products company generated revenue of $53.7 million during the period and anticipates full-year revenue to be between $227 million and $231 million.
Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System
Cerus Corporation has signed a new four-year supply agreement with Établissement Français du Sang (EFS), the French Blood Establishment, for its INTERCEPT Blood System, including the next-generation INT200 illumination device. This agreement reinforces EFS's commitment to pathogen inactivation technologies for blood safety, with the INTERCEPT system having been in use in France since 2006. The collaboration ensures the continued provision of safe blood components, especially platelets, across continental France and its overseas territories.
Cerus: Q1 Earnings Snapshot
Cerus Corp. reported a first-quarter loss of $1.6 million, or 1 cent per share, on revenue of $53.7 million. The biomedical products company, based in Concord, California, anticipates full-year revenue to be between $227 million and $231 million.
Cerus Corp 1Q 2026: Revenue $59.9M, EPS $(0.01) — 10-Q Summary
Cerus Corp reported first-quarter 2026 results with revenue of $59.9M, a 23% year-over-year increase, and a narrowed net loss of $1.64M compared to $7.72M in Q1 2025. Diluted EPS for the quarter was $(0.01). The company saw growth in product sales, particularly disposable platelet kits, and is shifting towards IFC kit sales to blood centers, while also making progress in R&D and contract revenue.
Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System
Cerus Corporation has signed a new four-year supply agreement with Établissement Français du Sang (EFS), the French Blood Establishment, for its INTERCEPT Blood System. The agreement covers the INTERCEPT Blood System for platelets and plasma, including the next-generation INT200 illumination device. This partnership reinforces EFS's commitment to pathogen inactivation technologies for blood safety, with Cerus aiming to further expand the adoption of its blood safety solutions.
Cerus signs four-year supply deal with French blood service
Cerus Corporation has secured a four-year supply agreement with Établissement Français du Sang (EFS), France’s national blood establishment, for its INTERCEPT Blood System. This system, which includes components for platelets and plasma and the INT200 illumination device, has been utilized by EFS since 2006, with nationwide adoption in 2017. The deal comes as Cerus has seen its stock rise significantly and recently surpassed revenue expectations in its Q4 2025 financial report.
Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System
Cerus Corporation has signed a new four-year supply agreement with Établissement Français du Sang (EFS), the French Blood Establishment, for its INTERCEPT Blood System. This agreement covers both platelets and plasma as well as the new LED-based INT200 illumination device. The INTERCEPT system has been utilized in France since 2006 to safeguard the blood supply and is used in French overseas territories for maintaining safe platelet supplies during outbreaks like chikungunya, dengue, and Zika.
Cerus (CERS) to Release Earnings on Thursday
Cerus (CERS) is slated to release its Q1 2026 earnings on Thursday, April 30th, with analysts anticipating an EPS of ($0.03) and revenue of $55.678 million. Recent insider selling includes CEO William Mariner Greenman selling 447,757 shares, contributing to over $2.1 million in insider sales in the last 90 days. The stock currently trades at $1.94, and analyst consensus rates it as "Reduce."
[ARS] CERUS CORP SEC Filing
This article announces an ARS SEC filing by Cerus Corp (CERS) on April 22, 2026, which has a low filing impact and neutral sentiment. It provides an overview of the company's recent news, SEC filings, and stock data. The filing itself is available as a PDF document from the SEC EDGAR database.
Cerus (NASDAQ: CERS) seeks equity plan approval and board re-election
Cerus Corporation is calling a virtual annual meeting on June 2, 2026, for stockholders to vote on key proposals including the re-election of two directors, an expansion of its 2024 Equity Incentive Plan by 10 million shares, advisory approval of executive compensation, and the ratification of Ernst & Young LLP as auditor for 2026. The company reported strong 2025 financial results with $206.1 million in product revenue, a narrowed GAAP net loss of $15.6 million, and positive non-GAAP adjusted EBITDA of $9.5 million. The proxy statement also highlights Cerus's INTERCEPT Blood System franchise and ongoing developments, including progress in its red blood cell system and new leadership transitions.
Cerus appoints severance agreements for Kevin D. Green, Vivek Jayaraman, Richard Benjamin and Chrystal N. Jensen
Cerus has adopted a new severance plan and entered into individual participation agreements with four key executives: CFO Kevin D. Green, COO Vivek Jayaraman, CMO Richard Benjamin, and CLO Chrystal N. Jensen. These agreements, effective April 17, 2026, supersede prior arrangements and are part of their participation in the newly adopted Severance Plan. The details of their replacement information are not disclosed in the filing.
Cerus (NASDAQ: CERS) sets richer change-of-control severance for executives
Cerus Corporation has implemented a new executive severance plan for its senior officers, standardizing payouts in cases of termination without cause or resignation for good reason, especially following a change of control. The plan enhances severance benefits for the CFO, COO, Chief Medical Officer, and Chief Legal Officer, providing lump sum payments, COBRA premiums, and accelerated equity vesting. Notably, Chief Executive Officer Vivek Jayaraman receives even richer benefits under change-of-control scenarios.
Sumitomo Mitsui Trust Group Inc. Sells 975,218 Shares of Cerus Corporation $CERS
Sumitomo Mitsui Trust Group Inc. reduced its stake in Cerus Corporation by 17.2%, selling 975,218 shares in Q4, reducing its holdings to 4,709,959 shares valued at $9.7 million. Company insiders, including the CFO and CEO, also sold a significant number of shares totaling $2.11 million over the past 90 days, though insiders still own 5.60% of the stock. Despite reporting quarterly EPS in line with estimates and revenue beating expectations, Cerus remains unprofitable, with analysts holding a "Reduce" consensus rating.
Cerus sets April 30 earnings release, 4:30 p.m. ET webcast
Cerus Corporation announced it will release its first quarter 2026 financial results on Thursday, April 30, 2026, after the market closes. The company will host a conference call and webcast at 4:30 P.M. ET on the same day to discuss the results, provide a business overview, and an outlook. Interested parties can access the live webcast via the Investor Relations page of the Cerus website.
Cerus Corporation to Release First Quarter 2026 Financial Results on April 30, 2026
Cerus Corporation announced it will release its first quarter 2026 financial results on April 30, 2026, after the stock market closes. The company will host a conference call and webcast at 4:30 P.M. ET on the same day to discuss the results and provide a business overview. Interested parties can register for the call via the Investor Relations page of the Cerus website.
Cerus (CERS) Chief Legal Officer receives 200,000-share RSU stock grant
Cerus Corp.'s Chief Legal Officer, Chrystal Jensen, was granted 200,000 Restricted Stock Units (RSUs) as a stock-based compensation award on April 1, 2026. These RSUs, valued at $0.00 per share for compensation purposes, will vest in full one year from the grant date, provided Jensen remains in continuous service. Following this grant, Jensen directly holds 1,146,131 shares of Cerus common stock, reinforcing her equity stake in the company.
Cerus (CERS) CFO receives 200,000-share RSU grant, lifts holdings to 1.24M
Cerus Corporation's Chief Financial Officer, Kevin Dennis Green, has received a grant of 200,000 Restricted Stock Units (RSUs) of common stock. This grant, valued at $0.00 per share as a compensation award, will vest fully one year from the grant date, subject to his continuous service to the company. Following this transaction, Green's direct holdings in Cerus common shares have increased to 1,240,551.
CERS SEC Filings - Cerus 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to SEC filings for Cerus Corporation (NASDAQ: CERS), including 10-K, 10-Q, and 8-K forms. It offers detailed financial information, business risks, and corporate governance updates, enhanced with AI-powered summaries and impact analysis for investors. Recent filings include an amended 13G/A from Baker Brothers disclosing Cerus shares and an 8-K detailing a leadership transition where the CEO assumed the chair role.
CERS Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Cerus Corp (CERS) from Intellectia.AI. It indicates a "Strong Buy" consensus based on various technical signals, including moving averages and oscillators. The analysis details key momentum indicators, support and resistance levels, and Cerus Corp's performance relative to its moving averages.
Cerus Corp (CERS) Stock Price Quote Today & Current Price Chart
This article provides the current stock price quote and chart for Cerus Corp (CERS). It is hosted on Capital.com, an online trading platform.
Vanguard disaggregates holdings after realignment; Cerus Corp (NASDAQ: CERS)
Vanguard has filed an amended Schedule 13G/A, reporting a 0% beneficial ownership in Cerus Corp (NASDAQ: CERS) following an internal realignment that took effect on January 12, 2026. This realignment means that certain Vanguard subsidiaries will now report their holdings separately. The filing indicates that Vanguard itself no longer holds voting or dispositive power over Cerus Corp shares.
Soleus Capital (NASDAQ: CERS) discloses 5.1% position in Cerus
Soleus Capital Master Fund, L.P. and its affiliated entities have reported a 5.1% beneficial ownership stake in Cerus Corporation (NASDAQ: CERS), totaling 9,828,700 shares. This disclosure, filed as a SCHEDULE 13G, indicates shared voting and dispositive power over these shares among Soleus entities and Guy Levy. The ownership percentage is calculated based on 192,171,776 shares of Cerus common stock outstanding as of February 5, 2026.
Cerus Corp CEO Greenman sells $742k in shares
Cerus Corp CEO William Mariner Greenman sold 447,757 shares of common stock worth $742,022. The sale was primarily to cover tax obligations and brokerage fees related to restricted stock units, not a discretionary action. This transaction follows recent company news including strong Q4 2025 financial results and a planned leadership transition with Vivek Jayaraman succeeding Greenman as CEO in July 2026.
Cerus (CERS) COO share sale covers taxes on RSU vesting
Cerus Corp's Chief Operating Officer, Vivek K. Jayaraman, sold 165,200 shares of common stock at a weighted average price of $1.6572 per share on March 12, 2026. This transaction was conducted under a Rule 10b5-1 instruction to cover tax withholding obligations and brokerage fees associated with the vesting of restricted stock units, and was not a discretionary sale. Following the sale, Jayaraman directly holds 1,747,674 shares of Cerus common stock.
Cerus Appoints Vivek Jayaraman As Chief Executive Officer
Cerus Corp. has announced that Vivek Jayaraman, its current chief operating officer, will become president and chief executive officer, effective July 1, 2026. Current CEO William “Obi” Greenman will transition to executive chairman of the board. Jayaraman, who joined Cerus in 2016, has been instrumental in growing the company's annual product revenue from under $40 million to over $200 million.
Cerus Corp COO Jayaraman sells $273k in shares By Investing.com
Cerus Corp Chief Operating Officer Vivek K. Jayaraman sold 165,200 shares of common stock for $273,769, primarily to cover tax obligations. Despite the sale, he still directly owns 1,747,674 shares, and the company's stock shows volatility with a 43% 6-month return. Jayaraman is also set to become Cerus Corporation's new President and CEO effective July 1, 2026.
Jensen, Cerus Corp chief legal officer, sells $187k in stock
Jensen Chrystal, Chief Legal Officer of Cerus Corp (NASDAQ:CERS), sold 113,008 shares of company stock for a total of $187,276 on March 12, 2026. This transaction comes as the company recently reported strong Q4 2025 financial results, exceeding revenue projections, and announced a new President and CEO, Vivek Jayaraman, effective July 2026. Despite the insider sale and a recent stock dip, InvestingPro analysis suggests the stock is currently undervalued.
Cerus Corp COO Jayaraman sells $273k in shares
Cerus Corp's COO, Vivek K. Jayaraman, sold 165,200 shares of common stock for $273,769 on March 12, 2026, as part of a tax obligation plan. Despite a year-to-date decline, the stock has seen a 43% return over six months and is considered undervalued by InvestingPro. Jayaraman is also set to become the company's new President and CEO effective July 1, 2026.
Cerus (CERS) CEO sells 447,757 shares under 10b5-1 tax plan
Cerus Corp. President and CEO William Mariner Greenman sold 447,757 shares of common stock on March 12, 2026, at a weighted average price of $1.6572 per share. This sale was conducted under a Rule 10b5-1 plan to cover statutory tax withholding obligations and brokerage fees related to the vesting of restricted stock units, and was not a discretionary transaction. Following the sale, Greenman directly owns 4,998,493 shares of Cerus common stock.
Cerus (CERS) CFO share sale covers taxes on RSU vesting
Cerus Corporation's CFO, Kevin Dennis Green, reported an open-market sale of 127,544 shares of Common Stock at a weighted average price of $1.6572 per share. This sale was conducted under a Rule 10b5-1 instruction to cover statutory tax withholding obligations and brokerage fees related to the vesting of restricted stock units, and was not a discretionary sale. Following this transaction, Green directly holds 1,040,551 shares of Cerus common stock.
